Alnylam Pharma (ALNY) Stock Forecast & Price Target

Compare

1,252 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALNY Analyst Ratings

Strong Buy

19 Buy

4 Hold

0 Sell

Based on 23 analysts giving stock ratings to

Alnylam

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALNY Stock 12 Month Forecast

Average Price Target

$328.41

▲(6.38%Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $328.41 with a high forecast of $500.00 and a low forecast of $245.00. The average price target represents a 6.38% change from the last price of $308.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"147":"$147","324":"$324","501":"$501","235.5":"$235.5","412.5":"$412.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$500.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":328.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$328.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$245.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[147,235.5,324,412.5,501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,306.09,321.00615384615384,335.9223076923077,350.8384615384615,365.75461538461536,380.6707692307692,395.5869230769231,410.50307692307695,425.41923076923075,440.3353846153846,455.2515384615385,470.1676923076923,485.08384615384614,{"y":500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,306.09,307.80692307692306,309.52384615384614,311.2407692307692,312.9576923076923,314.6746153846154,316.39153846153846,318.10846153846154,319.8253846153846,321.5423076923077,323.2592307692308,324.97615384615386,326.69307692307694,{"y":328.41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,306.09,301.3907692307692,296.6915384615384,291.9923076923077,287.2930769230769,282.59384615384613,277.89461538461535,273.1953846153846,268.49615384615385,263.79692307692306,259.0976923076923,254.39846153846153,249.69923076923078,{"y":245,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":148.43,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.32,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":306.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$500.00

Average Price Target$328.41

Lowest Price Target$245.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$327

Hold

5.92%

Upside

Reiterated

06/05/25

Alnylam Pharmaceuticals is showing promising revenue growth and strong technical momentum, contributing positively to its stock score. However, high leverage, ongoing profitability challenges, and a negative P/E ratio weigh down the overall evaluation. The company's strategic focus on achieving sustainable profitability and recent successful product launches provide optimism, but caution is advised due to financial and regulatory risks.

Luca IssiRBC Capital

RBC Capital

$330

Buy

6.90%

Upside

Reiterated

06/13/25

RBC Capital Remains a Buy on Alnylam Pharma (ALNY)

Jessica FyeJ.P. Morgan

J.P. Morgan

$330→$338

Buy

9.49%

Upside

Reiterated

06/12/25

Alnylam price target raised to $338 from $330 at JPMorganAlnylam price target raised to $338 from $330 at JPMorgan

Michael UlzMorgan Stanley

Morgan Stanley

$287

Hold

-7.03%

Downside

Reiterated

06/09/25

Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$400→$500

Buy

61.96%

Upside

Reiterated

06/03/25

Alnylam Pharma's Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook

Gena WangBarclays

Barclays

$329

Buy

6.57%

Upside

Reiterated

05/27/25

Alnylam Pharma (ALNY) Receives a Buy from Barclays

Ritu BaralTD Cowen

TD Cowen

$371

Buy

20.18%

Upside

Reiterated

05/19/25

TD Cowen Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

David LebowitzCiti

Citi

$351→$364

Buy

17.91%

Upside

Reiterated

05/19/25

Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$345

Buy

11.76%

Upside

Reiterated

05/14/25

Stifel Nicolaus Keeps Their Buy Rating on Alnylam Pharma (ALNY)

Liisa BaykoEvercore ISI

Evercore ISI

$280

Buy

-9.30%

Downside

Reiterated

05/06/25

Evercore ISI Keeps Their Buy Rating on Alnylam Pharma (ALNY)

Kostas BiliourisBMO Capital

BMO Capital

$300

Buy

-2.82%

Downside

Reiterated

05/06/25

Alnylam Pharma's Strong Market Position and Amvuttra's Impressive Sales Growth Drive Buy Recommendation

Keay NakaeChardan Capital

Chardan Capital

$300→$325

Buy

5.28%

Upside

Reiterated

05/02/25

Alnylam Pharma (ALNY) Gets a Buy from Chardan Capital

Greg HarrisonScotiabank

Scotiabank

$342

Buy

10.78%

Upside

Reiterated

05/02/25

Scotiabank Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Eliana MerleUBS

UBS

$331→$349

Buy

13.05%

Upside

Reiterated

05/02/25

Alnylam price target raised to $349 from $331 at UBSAlnylam price target raised to $349 from $331 at UBS

Edward TenthoffPiper Sandler

Piper Sandler

$304

Buy

-1.53%

Downside

Reiterated

05/02/25

Piper Sandler Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$327

Hold

5.92%

Upside

Reiterated

06/05/25

Luca IssiRBC Capital

RBC Capital

$330

Buy

6.90%

Upside

Reiterated

06/13/25

RBC Capital Remains a Buy on Alnylam Pharma (ALNY)

Jessica FyeJ.P. Morgan

J.P. Morgan

$330→$338

Buy

9.49%

Upside

Reiterated

06/12/25

Alnylam price target raised to $338 from $330 at JPMorganAlnylam price target raised to $338 from $330 at JPMorgan

Michael UlzMorgan Stanley

Morgan Stanley

$287

Hold

-7.03%

Downside

Reiterated

06/09/25

Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$400→$500

Buy

61.96%

Upside

Reiterated

06/03/25

Alnylam Pharma's Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook

Gena WangBarclays

Barclays

$329

Buy

6.57%

Upside

Reiterated

05/27/25

Alnylam Pharma (ALNY) Receives a Buy from Barclays

Ritu BaralTD Cowen

TD Cowen

$371

Buy

20.18%

Upside

Reiterated

05/19/25

TD Cowen Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

David LebowitzCiti

Citi

$351→$364

Buy

17.91%

Upside

Reiterated

05/19/25

Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$345

Buy

11.76%

Upside

Reiterated

05/14/25

Stifel Nicolaus Keeps Their Buy Rating on Alnylam Pharma (ALNY)

Liisa BaykoEvercore ISI

Evercore ISI

$280

Buy

-9.30%

Downside

Reiterated

05/06/25

Evercore ISI Keeps Their Buy Rating on Alnylam Pharma (ALNY)

Kostas BiliourisBMO Capital

BMO Capital

$300

Buy

-2.82%

Downside

Reiterated

05/06/25

Alnylam Pharma's Strong Market Position and Amvuttra's Impressive Sales Growth Drive Buy Recommendation

Keay NakaeChardan Capital

Chardan Capital

$300→$325

Buy

5.28%

Upside

Reiterated

05/02/25

Alnylam Pharma (ALNY) Gets a Buy from Chardan Capital

Greg HarrisonScotiabank

Scotiabank

$342

Buy

10.78%

Upside

Reiterated

05/02/25

Scotiabank Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Eliana MerleUBS

UBS

$331→$349

Buy

13.05%

Upside

Reiterated

05/02/25

Alnylam price target raised to $349 from $331 at UBSAlnylam price target raised to $349 from $331 at UBS

Edward TenthoffPiper Sandler

Piper Sandler

$304

Buy

-1.53%

Downside

Reiterated

05/02/25

Piper Sandler Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

1 Month

xxx

Success Rate

15/26 ratings generated profit

Average Return

+0.78%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.69% of your transactions generating a profit, with an average return of +0.78% per trade.

3 Months

xxx

Success Rate

20/29 ratings generated profit

Average Return

+9.84%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.97% of your transactions generating a profit, with an average return of +9.84% per trade.

1 Year

Kostas BiliourisBMO Capital

Success Rate

18/20 ratings generated profit

Average Return

+25.48%

reiterated a buy rating last month

Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +25.48% per trade.

2 Years

xxx

Success Rate

20/20 ratings generated profit

Average Return

+47.79%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +47.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALNY Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALNY has received 36 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the past 3 months is 328.41.

Each month's total comprises the sum of three months' worth of ratings.

ALNY Financial Forecast

ALNY Earnings Forecast

Next quarter’s earnings estimate for ALNY is -$0.66 with a range of -$1.34 to $0.70. The previous quarter’s EPS was -$0.44. ALNY beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.

ALNY Sales Forecast

Next quarter’s sales forecast for ALNY is $634.44M with a range of $562.00M to $704.00M. The previous quarter’s sales results were $594.19M. ALNY beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.

ALNY Stock Forecast FAQ

What is ALNY’s average 12-month price target, according to analysts?

Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 328.41.

What is ALNY’s upside potential, based on the analysts’ average price target?

Alnylam Pharmaceuticals has 6.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALNY a Buy, Sell or Hold?

Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.

What is Alnylam Pharmaceuticals’s price target?

The average price target for Alnylam Pharmaceuticals is 328.41. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $500.00 ,the lowest forecast is $245.00. The average price target represents 6.38% Increase from the current price of $308.71.

What do analysts say about Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of ALNY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alnylam Pharma (ALNY) Stock Forecast & Price Target

ALNY Analyst Ratings

ALNY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alnylam Pharma

ALNY Analyst Recommendation Trends

ALNY Financial Forecast

ALNY Earnings Forecast

ALNY Sales Forecast

ALNY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts